FDA to consider warning against antidepressants

Is the FDA about to keep pregnant women from taking antidepressants?

A newly-constituted panel repeated what one women’s health expert called “MAHA talking points.”

FDA panel elevates concerns over antidepressant use during pregnancy

Experts on the panel shared many of the same views around SSRIs, arguing the risks of the drugs during pregnancy are greater than currently accepted.

FDA panel promotes misinformation about antidepressants during pregnancy, psychiatrists say

A Food and Drug Administration panel discussing the use of antidepressants during pregnancy Monday largely amounted to misinformation or facts taken out of context, according to several psychiatrists who tuned in to the meeting.

FDA to Consider Warning Against Antidepressants

by Andrew Rice   Doctors on Monday urged the U.S. Food and Drug Administration to issue warnings to pregnant women against the use of certain medications to treat depression, obsessive compulsive disorder and anxiety. In a panel discussion Monday, doctors across the medical field and officials at the FDA said women taking selective serotonin reuptake inhibitors to treat illnesses like depression can negatively impact the development of a child i…

FDA Panel Takes Aim at SSRI Use During Pregnancy

(MedPage Today) -- Women should be better informed about the potential risks of using selective serotonin reuptake inhibitors (SSRIs) during pregnancy, and these risks should be weighed against their benefits, most speakers on an FDA panel selected...

FDA panel weighs risks, benefits of antidepressants during pregnancy

Members of an FDA expert panel discussed the risks and benefits of selective serotonin reuptake inhibitors, or SSRIs, for depression during pregnancy, with some calling for stronger warning labels.